| Name | NU6140 |
| Description | NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM). It shows 10- to 36-fold selectivity over other CDKs. NU6140 also effectively inhibits Aurora A and Aurora B (IC50s: 67 and 35 nM, respectively). It also enhances the apoptotic effect and has anti-cancer activity. |
| In vitro | NU6140 enhances catalytic activity of capase-9 and capase-3, causes an increase in the sub-G1 apoptotic cell population. NU6140 is less active on CDK1-cyclin B, CDK4-cyclin D, CDK5-p25 and CDK7-cyclin H (IC50s: 6.6, 5.5, 15 and 3.9 μM, respectively)[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (591.69 mM), Sonication is recommended.
|
| Keywords | NU-6140 | NU6140 | NU 6140 | Inhibitor | inhibit | Cyclin dependent kinase | cdk7-cyclin H | cdk7/cyclinH | cdk5-p25 | cdk5/p25 | CDK4-Cyclin D | CDK4/CyclinD | cdk2-cyclin A | cdk2/cyclinA | CDK1-Cyclin B | CDK1/CyclinB | CDK | AuroraKinase | Aurora Kinase | Aurora B | Aurora A |
| Inhibitors Related | Ribociclib | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | SP600125 | 2,4,6-Trihydroxybenzoic acid | Palmatine | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Dinaciclib |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Active Compound Library |